Subsidiaries of China Resources Double-Crane Pharmaceutical (600062.SH), azithromycin dispersible tablets and sodium bicarbonate injection have passed the consistency evaluation.

China Resources Double-Crane Pharmaceutical (600062.SH) announced that its wholly-owned subsidiary China Resources Double-Crane Pharmaceutical Limin Pharmaceutical (Jinan) Co., Ltd. (referred to as "Shuanghe Limin") has received the "Drug Supplementary Application Approval Notice" (Notice No. 2025B00016, 2025B00105) issued by the National Medical Products Administration for Azithromycin dispersible tablets and Sodium Bicarbonate Injection. Azithromycin is a macrolide antibiotic used to treat mild to moderate infections caused by designated sensitive strains of microorganisms. Sodium Bicarbonate is an antacid medication used for treating metabolic acidosis; alkalinizing urine for the prevention of uric acid kidney stones; reducing the kidney toxicity of sulfonamide drugs; and as a non-specific treatment for certain drug poisonings when administered intravenously, such as barbiturates, salicylates, and methanol poisoning. The approval of Azithromycin dispersible tablets and Sodium Bicarbonate Injection through consistency evaluation will benefit future market sales and competition, and accumulate valuable experience for the subsequent evaluation of generic drugs.